Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2014, New Report Launched
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2014 report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.
View full press release